TMO earnings — 2026-07-22

Thermo Fisher's Q2 2026 print landed as a beat-and-raise: Yahoo Finance (2026-07-27) reports the stock climbing +8.7% on "solid earnings" and price-target upgrades, while Seeking Alpha and TipRanks (both 2026-07-27) independently frame it as a Q2 beat with a lifted outlook. The desk's own cross-wire detector flagged an 8-K filed 2026-07-23 landing on a +8.7% day at 2.7x average volume, and the July 25 and July 27 market briefs both describe TMO as crossing overbought on a Q2 beat-and-raise — but no source on disk states the actual EPS or revenue dollar figures, and the biotech-capital-cycle perspective log's 2026-07-28 entry explicitly flags the beat-and-raise as reported but unverified against a primary filing or transcript. Full-scan summaries dated 2026-07-28 (biotech-capital-cycle) show TMO at $576.41, RSI 70.3 (overbought), +10.1% over 7 days and +13.8% over 30 days, still -10.5% off its 52-week high. For the biotech-capital-cycle thesis this is domino #2 (TMO/DHR reagents and preclinical) moving to "reported bullish, unverified" alongside MEDP — one of the two prints the ratification gate was waiting on, not yet a fired confirmation.